Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury (NCT04633889) | Clinical Trial Compass
Active ā Not RecruitingPhase 2
Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury
United States320 participantsStarted 2021-04-13
Plain-language summary
Multiple lines of evidence support a central role of iron in causing acute kidney injury (AKI), including the finding that prophylactic administration of iron chelators attenuates AKI in animal models. Patients undergoing cardiac surgery may be particularly susceptible to iron-mediated kidney injury due to the profound hemolysis that often occurs from cardiopulmonary bypass. The investigators will test in a phase 2, randomized, double-blind, placebo-controlled trial whether prophylactic administration of deferoxamine decreases the incidence of AKI following cardiac surgery.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
ā. Age ā„18 years
ā. Undergoing coronary artery bypass graft and/or valve surgery with cardiopulmonary bypass
ā. AKI risk score ā„6 at the time of screening
ā. Written informed consent from the patient or surrogate
ā. Chronic iron overload (including conditions such as hemochromatosis and beta thalassemia major) or previous iron chelation therapy (including prior participation in DEFEAT-AKI)